Clinical Trials

72 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

125 enrolled 18 charts 2 FDA

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

12 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

568 enrolled

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-02-06

ASSURE-3

Active not recruiting

201 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05362773 2026-01-13

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

130 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT06163430 2026-01-12

CARDINAL

Phase 1/2 Recruiting

180 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

Available

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

104 enrolled 11 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

242 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07188428 2025-09-23

Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

2,298 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06514534 2025-09-22

ASC4TARGET

Phase 2 Recruiting

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04925479 2025-09-17

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1/2 Recruiting

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06986772 2025-09-04

TGRX-678 Pharmacokinetic Mass Balance

Phase 1 Completed

6 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07151820 2025-09-03

A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients

2,546 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07150793 2025-09-02

A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

754 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07145411 2025-08-28

HOPE

Recruiting

10 enrolled

Anemia, Aplastic, Anemia, Sickle Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06787144 2025-07-01

CML

21 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT06423911 2025-06-03

POLARIS-2

Phase 3 Recruiting

285 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06697899 2025-05-16

TGRX-678 Phase I Oral Pharmacokinetic Study

Phase 1 Completed

76 enrolled

Phase 1 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04013685 2025-05-02

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

255 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

84 enrolled

233 enrolled 10 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03106779 2025-04-08

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3 Completed

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04233346 2025-04-04

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

93 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05282108 2025-03-26

CARCML

Recruiting

240 enrolled

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

144 enrolled

Phase 1 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05434312 2025-02-24

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06088888 2025-02-21

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06453902 2025-02-21

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Phase 2 Recruiting

40 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase

NCT05943522 2025-01-14

Asciminib RMP Study

Recruiting

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04028479 2024-12-18

ROOT

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

167 enrolled

Nasopharyngeal Carcinoma, Adenocarcinoma, Adrenal Gland Neoplasms, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoid Tumor, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liposarcoma, Liver Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mesothelioma, Multiple Myeloma, Neoplasms, Multiple Endocrine Neoplasia, Neoplasms, Unknown Primary, Ovarian Neoplasms, Pancreatic Neoplasms, Parathyroid Neoplasms, Parotid Neoplasms, Penile Neoplasms, Pharyngeal Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Ureteral Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Central Nervous System Neoplasms, Cholangiocarcinoma, Carcinoma, Small Cell, Neuroendocrine Tumors, Brain Stem Neoplasms, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06692803 2024-11-18

ABL-2022-03

2,043 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05260203 2024-11-06

MargheRITA

Phase NA Completed

124 enrolled

Treatment Adherence and Compliance, Amyloidosis, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Neoplasms, Plasma Cell

NCT06672263 2024-11-04

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

Phase 1 Not yet recruiting

120 enrolled